Raoul S. Concepcion, MD, FACS, The Comprehensive Prostate Center, Nashville, Tennessee, gives an overview of the targeting of the androgen receptor in the management of prostate cancer.
To view slides from Dr. Concepcion’s presentation at the 18th Annual Future Directions in Urology Symposium, click here.
Keywords: prostate cancer, androgen receptor
ABOUT THE AUTHOR
Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee. He was a resident in General Surgery and Urology at Vanderbilt University from 1984-1990, and later served as a Clinical Associate Professor of Urology there.
Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President of LUGPA. Along with two other urologists, he founded CUSP, a urologic research consortium in the United States. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.
